Cancer patients who have an episode of<unk><unk>  should receive an extended anticoagulation therapy for at least 3 months.  The first line long term anticoagulation therapy for venous thromboembolism (VTE) in cancer patients is vitamin K antagonist (VKA) over low molecular weight heparin (LMWH).  Outpatient cancer patients with no additional risk factors for VTE should not receive any routine VTE prophylaxis.
Pulmonary embolism special scenario cancer
Sarcomatoid carcinoma of the lung risk factors
Non small cell lung cancer other diagnostic studies
Large cell carcinoma of the lung risk factors
Pulmonary edema differential diagnosis
Hemothorax future or investigational therapies
Adenocarcinoma of the lung risk factors
Squamous cell carcinoma of the lung other diagnostic studies